Free Trial

Aligos Therapeutics Q1 2024 Earnings Report

Aligos Therapeutics logo
$5.95 -0.53 (-8.18%)
As of 04/4/2025 04:00 PM Eastern

Aligos Therapeutics EPS Results

Actual EPS
-$5.50
Consensus EPS
-$4.75
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A

Aligos Therapeutics Revenue Results

Actual Revenue
$0.99 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aligos Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Aligos Therapeutics Earnings Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Aligos Therapeutics presents positive data at APASL2025
Ten option delistings on March 24th
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

View Aligos Therapeutics Profile

More Earnings Resources from MarketBeat